The startup is a biotechnology research firm focused on treating hard-to-treat cancers by utilizing biologics that inhibit tumor growth and reprogram the tumor microenvironment. Their approach targets a pan-cancer metabolic vulnerability, providing drugs that effectively starve tumors in lung and breast cancers.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers are difficult to treat due to their ability to evade the immune system and establish a microenvironment that supports tumor growth. Current therapies often fail to address the metabolic vulnerabilities that fuel cancer cell proliferation and resistance to treatment.
Solution
This biotechnology company is developing biologic therapies designed to inhibit tumor growth and reprogram the tumor microenvironment, specifically targeting a pan-cancer metabolic vulnerability. Their approach aims to starve tumors by disrupting key metabolic pathways essential for cancer cell survival and proliferation. By targeting the tumor microenvironment, the therapies also seek to enhance the effectiveness of other cancer treatments and prevent recurrence. The company's research focuses on developing novel biologics that can effectively target and disrupt these metabolic processes, leading to improved outcomes for patients with hard-to-treat cancers.
Target Audience
The primary target audience includes patients with hard-to-treat cancers, oncologists, and researchers in the field of cancer biology.
Features
- Biologic therapies targeting pan-cancer metabolic vulnerabilities.
- Drugs designed to starve tumors by disrupting key metabolic pathways.
- Reprogramming of the tumor microenvironment to enhance treatment efficacy.